Pregabalin: Difference between revisions

From SEHK Wiki
Helen (talk | contribs)
Helen (talk | contribs)
Line 70: Line 70:


Adverse drug reactions associated with the use of pregabalin include:
Adverse drug reactions associated with the use of pregabalin include:
{| class="wikitable"


{|class="wikitable"
|'''Very common''' (>10% of people with lamotrigine)  
!style="text-align: left"| Very common (>10% of people with pregabalin)
|Dizziness, drowsiness
|Dizziness, drowsiness
|-
|-
!style="text-align: left"|Common (1-10% of people with pregabalin)  
|'''Common''' (1-10% of people with lamotrigine)
|Blurred vision, diplopia,  
|Blurred vision, diplopia,  
Ataxia
Aggression
Agitation
Back pain
Tremor
Nausea and vomiting
|-
|-
|
|Rare (<0.1% of people with lamotrigine)
|Increased appetite and subsequent weight gain
|Blood disorders, anaemia, leucopenia
|-
 
|Euphoria
Exacerbation of Parkinson’s disease
|-
 
|Confusion
Hallucination
|-
 
|Memory impairment
Hepatic failure
|-
 
|Tremors
Hypersensitivity syndrome
|-
|Vertigo
|-
|Dry mouth and constipation
|-
|Vomiting and flatulence
|-
|Erectile dysfunction
|-
|Peripheral edema
|-
|Aataxia


|-
Lupus erythematosus-like reactions
!style="text-align: left"| Morphine
|Morphine reduces the clearance of gabapentin; patients receiving both drugs should be monitored for signs for CNS depression and doses should be reduced accordingly.
|}
|}

Revision as of 22:23, 5 October 2020

Pronunciation

Pregabalin 150mg

Pregabalin 25mg

Pregabalin 50mg


Introduction

Gabapentin is an anticonvulsant medication:

  • Peripheral and central neuropathic pain
  • Used as an adjunctive therapy for focal seizures with or without secondary generalization.
  • Generalized anxiety disorder


Mechanism of Action

Anticonvulsant medication. It inhibits the alpha 2-delta subunit of voltage-dependent calcium channels.


Generic Name 藥名 HA Code 藥物代碼 Classification藥物分類
Pregabalin Capsule 25mg PREG15 P1S1S3


Dosage

Epilepsy

By mouth the initial oral dose is 25 mg twice daily, increased at weekly intervals in steps of 50 mg daily to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.


Neuropathic Pain

By mouth initially 150 mg daily in 2-3 divided doses, increased if necessary after 3-7 days to 300 mg daily in 2-3 divided doses, increased further if necessary after 7 days to max. 600 mg daily in 2-3 divided doses.

Alternatively, 300 mg 3 times daily on day 1, then increased according to response in steps of 300mg (in 3 divided doses) every 2-3 days up to max. 3.6 g daily.


Generalized anxiety disorder

By mouth initially 150 mg daily in 2-3 divided doses, increased if necessary at weekly intervals in steps of 150 mg daily; max. 600 mg daily in 2-3 divided doses.


As with other antiepileptics, withdrawal of prgabalin therapy or transition to or from another type of antiepileptic therapy should be made gradually to avoid precipitating an increase in seizure frequency.


Side Effects

Adverse drug reactions associated with the use of pregabalin include:

Very common (>10% of people with lamotrigine) Dizziness, drowsiness
Common (1-10% of people with lamotrigine) Blurred vision, diplopia,

Ataxia

Aggression

Agitation

Back pain

Tremor

Nausea and vomiting

Rare (<0.1% of people with lamotrigine) Blood disorders, anaemia, leucopenia

Exacerbation of Parkinson’s disease

Hallucination

Hepatic failure

Hypersensitivity syndrome

Lupus erythematosus-like reactions